PRIMARY STUDY

Renoprotective effects of febuxostat in hyperuricemic patients with chronic kidney disease: a parallel-group, randomized, controlled trial

Key Findings:  In patients with chronic kidney disease (CKD) and hyperuricemia, treatment with the novel non-purine, selective xanthine oxidase inhibitor called Febuxostat, reduced serum uric acid (UA) levels in the blood, and reduced liver-type fatty acid-binding protein (L-FABP), albumin, and beta 2 microglobulin β2MG in the urine, suggesting it's therapeutic potential and renoprotective properties.